Kidney patients will be prevented from EU travel under no-deal Brexit

  • More than 25,500 haemodialysis patients will face prohibitive costs for life-sustaining treatment if the UK leaves the EU without a deal
  • Dialysis is not covered by travel insurance, but is supported under existing European Health Insurance Card scheme
  • Experts and charity call on government to address lack of reciprocal healthcare agreements with EU countries

Man on dialysis

Kidney patients could be prevented from travelling to European Union countries in the event of a no-deal Brexit, according to a new report.

Academic experts and students at the University of Sheffield, working with leading charity Kidney Care UK, found that if there is no withdrawal agreement, and no reciprocal healthcare arrangements are made with EU countries before the end of October 2019, UK haemodialysis patients will not be able to travel in Europe unless they pay around £900 a week (£300 per session) for the treatments they need to stay alive.

There is no travel insurance available for dialysis, because it is planned life-sustaining treatment for a pre-existing condition – but haemodialysis is currently covered through the European Health Insurance Card (EHIC). There are currently 25,533 people in the UK on haemodialysis, who would all face prohibitive care costs if they wanted to travel to EU countries in a no-deal scenario.

Patients with kidney problems require haemodialysis to stay alive because when someone’s kidneys don’t work properly, toxins build up in their bloodstream. The treatment works by taking blood from the body and running it through a filter in a machine to ‘clean’ it. Toxins move from the blood into dialysis fluid and the dialysis fluid is then disposed of. Dialysis sessions usually take around three to four hours at a time and have to be done three to four times a week to keep kidney patients alive.

Should a withdrawal agreement be reached, the EU law upholding UK citizens’ rights to access cross-border healthcare will continue to support dialysis patients until 31 December 2020 – or longer if the transition period is extended. However, a no-deal Brexit will immediately remove the rights of UK dialysis patients to access free treatment in EU countries.

While the UK Government has indicated it wishes to continue with reciprocal healthcare agreements, this has not been accepted by the EU given its current negotiating mandate. If bilateral agreements on reciprocal healthcare with individual member countries are likewise not agreed, UK patients would need to rely on the domestic laws of the countries they visit, with no supporting administrative structures.

Professor Tamara Hervey, co-author of the report and Professor of European Union Law at the University of Sheffield, said: “Bland statements from government that we are ready for no deal are not reassuring to vulnerable people – like kidney patients – whose legal position will change. We urgently need detailed and specific responses from government on this – among all the many issues that arise for health in the event of Brexit – especially a no-deal Brexit.”

Fiona Loud, Policy Director at Kidney Care UK, said: “Every kidney patient should be able to travel, but if we do not have reciprocal healthcare arrangements with the EU post-Brexit this will be severely curtailed for those on haemodialysis. With the UK still to reach healthcare agreements with any EU countries, patients have been left in limbo. With less than two months to go, thousands of kidney patients still do not know if they will be able to travel in Europe after Brexit.

“Without comprehensive agreements, most of the 25,500 kidney patients relying on haemodialysis will no longer be able to go to the EU due to the crippling costs of treatment. This is simply not acceptable. We need the government to address the issue of reciprocal healthcare as a priority. Today’s Healthcare after Brexit report underlines this need.”

The report was funded by the Economic Social Research Council and the University of Sheffield’s Sheffield Undergraduate Research Experience programme. Its findings should not be treated as legal advice and are subject to change.

Additional information

Facts and statistics about kidney disease.

The University of Sheffield

With almost 29,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world’s leading universities.

A member of the UK’s prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.

Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.

Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2018 and for the last eight years has been ranked in the top five UK universities for Student Satisfaction by Times Higher Education.

Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.

Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.

Contact

For further information please contact:

Sophie Armour
Media and PR Officer
0114 222 3687
07751 400 287
sophie.armour@sheffield.ac.uk